Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
Conclusion Our results suggest that the screening of rs12979860 may remain interesting for decision making in prior relapse HCV-1 Caucasian patients with compensated cirrhosis eligible for a telaprevir- or boceprevir-based therapy.
Source: PLoS One - Category: Biomedical Science Authors: Frédégonde About et al. Source Type: research
More News: Anemia | Biomedical Science | Cirrhosis | Genetics | Hepatitis | Hepatitis C | Incivek | Study | Virology